This tool provides public access to interactive data on drug utilization in Ontario during the COVID-19 pandemic. This update includes data up to February 2022 (opioids, benzodiazepines, and stimulants up to December 2021).
Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study
This study examined the impact of the publicly funded Ontario Naloxone Program for Pharmacies (ONPP), implemented in June 2016, on provincial rates of opioid overdose deaths.
International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID-19 pandemic: A cross-sectional analysis of 66 countries
This study compares trends in opioid purchasing between developed and developing economies to understand patterns of opioid consumption, and how they were impacted by the COVID-19 pandemic.
Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis
This study investigated the impact of the pandemic and the associated changes in OAT guidance on treatment discontinuation.